Expression of fas antigen in acute myeloid leukemia and its clinical imorttance
New Egyptian Journal of Medicine [The]. 1997; 16 (4): 340-343
Dans Anglais
| IMEMR
| ID: emr-46214
ABSTRACT
Flow cytometric immunofluorescent analysis was used to assess Fas antigen [CD95] expression in blasts obtained from bone marrow of 24 patients with acute myeloid leukemia. The percentage of positive cells in each sample was highly variable. Fas antigen expression did nor correlate with age Hb% concentration, while blood cell count, platelet count, blast% in peripheral blood, blast% in bone marrow, CD34 expression or BC12 protein. Low expression of Fas was associated with a low complete remission rate after induction chemotherapy [69.2% in cases with <20% positive cells versus 90.9% in cases with >/20% positive cells, P <0.01]. The main cause for not achieving remission was resistant diseases. The result of this study suggested that the quantitation of Fas expression can be predictive of treatment outcome in acute myeloid leukemia
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Leucémie aigüe myéloïde
/
Apoptose
/
Antigènes CD95
Type d'étude:
Guide de pratique
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
New Egypt. J. Med.
Année:
1997
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS